Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
Sara Hurvitz, MD, FACP:
I think the biggest data presented at the virtual SABCS 2020 meeting were the RxPONDER data, as this is the first randomized data in the node‑positive setting to demonstrate that we can possibly safely omit chemotherapy in a subset of our patients with early stage hormone receptor–positive/HER2-negative breast cancer.
Overall, looking at the compilation of the studies presented, we are making a dent in our ability to optimize and personalize therapies for patients with breast cancer based on their individualized risk.
Joyce O’Shaughnessy, MD:
I agree; the RxPONDER trial and the ADAPT trial were equally important in terms of understanding the biology and predicted ET sensitivity of patients’ early stage breast cancers. In addition, the RSClin algorithm that we can use to estimate distant recurrence risk at 10 years and absolute benefit of adjuvant chemotherapy on dRFS is very important and useful. Finally, I hope that we will see the approval of tesetaxel as a new oral taxane therapy for our patients with metastatic breast cancer.